Tesla Inc. (NASDAQ: TSLA) tumbled 6.3% on Tuesday to $328.50, its lowest level since November, extending its decline as the worst-performing “Magnificent Seven” stock in 2025. Shares dipped another 0.5% in after-hours trading, with the EV giant down 13.4% year-to-date, significantly underperforming the S&P 500’s 3.4% gain.
Once buoyed by optimism over CEO Elon Musk’s role in the Trump administration, Tesla now faces mounting concerns over its fundamentals. January sales in China plunged 33% month-over-month, highlighting the automaker’s first-ever annual decline in deliveries in 2024. Competition from BYD (SZ:002594), which now offers its advanced “God’s Eye” autonomous driving system on EVs priced under $10,000, further pressures Tesla. By contrast, Tesla’s similar features start at $32,000 in China, limiting its edge in the market.
Musk’s growing focus on ventures outside Tesla adds to investor unease. His recent $100 billion bid for OpenAI, which was swiftly rejected, reignited tensions between Musk and OpenAI CEO Sam Altman. Additionally, concerns over Musk balancing Tesla with his duties in the Department of Government Efficiency, xAI, and social media platform X have weighed on investor confidence.
Further complicating Tesla’s outlook, President Trump’s newly approved 25% tariffs on steel and aluminum—critical materials for Tesla’s production—add cost pressures to an already challenging market environment.
As BYD gains ground in China and Musk’s commitments remain divided, Tesla’s struggles continue, raising questions about its future growth and market dominance.


TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
AFT Leaves X Over AI-Generated Images of Minors
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
BlueScope Steel Announces A$1 Special Dividend After Asset Sales
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Starlink Internet Remains Active in Iran Despite Nationwide Blackout
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 



